ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis

BACKGROUND: Emerging mutations in the ESR1 gene that encodes for the estrogen receptor (ER) are associated with resistance to endocrine therapy. ESR1 mutations rarely exist in primary tumors (~ 1%) but are relatively common (10–50%) in metastatic, endocrine therapy-resistant cancers and are associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zundelevich, Adi, Dadiani, Maya, Kahana-Edwin, Smadar, Itay, Amit, Sella, Tal, Gadot, Moran, Cesarkas, Karen, Farage-Barhom, Sarit, Saar, Efrat Glick, Eyal, Eran, Kol, Nitzan, Pavlovski, Anya, Balint-Lahat, Nora, Dick-Necula, Daniela, Barshack, Iris, Kaufman, Bella, Gal-Yam, Einav Nili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998824/
https://www.ncbi.nlm.nih.gov/pubmed/32014063
http://dx.doi.org/10.1186/s13058-020-1246-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998824/
https://www.ncbi.nlm.nih.gov/pubmed/32014063
http://dx.doi.org/10.1186/s13058-020-1246-5

Ejemplares similares